Pituitary Preceptorship: How do I decide when to discontinue cabergoline therapy in prolactinomas
Pituitary Preceptorship: How do I decide when to discontinue cabergoline therapy in prolactinomas
Dr Greisa Vila
The educational content presented and discussed during the meeting are now available.Dr Greisa Vila
Endocrinologist
Medical University of Vienna
Austria
Dr Vila is Associate Professor of Medicine at the Medical University of Vienna, Austria. She graduated at the University of Tirana, Albania, and obtained her doctor’s degree at the Ludwig Maximilian University of Munich, Germany in 2004 with a translational thesis on the role of Sonic hedgehog signaling on corticotroph function and pituitary adenomas. She previously worked in the Division of Endocrinology, Hospital Saint-Antoine, Paris (2000-2001) and the Neuroendocrinology Group of the Max-Planck-Institute of Psychiatry in Munich (2002-2005), before joining the Division of Endocrinology at the Vienna General Hospital in 2006. Her primary clinical and research interests are pituitary diseases, and in particular neuroendocrine-metabolic interactions.
|
15 min
|accreditation:
EACCME |
Nov 2021
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
This programme is supported by an Independent Educational Grant from Ipsen
PITUITARY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Ipsen.